You just read:

Achieve Life Sciences Announces Completion of Enrollment in 254-Subject Phase 2b Trial of Cytisinicline for Smoking Cessation

News provided by

Achieve Life Sciences, Inc.

Feb 20, 2019, 05:30 ET